K. Wheatley

Rajan K. Patel, J. Cleland, P. Mark, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Use of standardized flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia

M. Pallis, J. Turzanski, S. Langabeer, 1999, British journal of haematology.

Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.

E. Frew, N. Ives, C. Cummins, 2019, Health technology assessment.

Adjuvant interferon-alpha in malignant melanoma: current status.

M. Gore, K. Wheatley, B. Hancock, 2000, Cancer treatment reviews.

Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial

R. Hills, N. Russell, A. Hunter, 2013, Leukemia.

reliability and utility for identifying disease subtypes Bone marrow pathology in essential thrombocythemia: interobserver

P. Campbell, A. Green, W. Erber, 2013 .

Haematologists' approaches to the management of adolescents and young adults with acute leukaemia

C. Stiller, K. Wheatley, S. Proctor, 2000, British journal of haematology.

Haematologists' approaches to the management of adolescents and young adults with acute leukaemia

C. Stiller, K. Wheatley, S. Proctor, 2000, British journal of haematology.

Bisphosphonates in multiple myeloma.

H. Goldschmidt, B. Djulbegovic, A. Glasmacher, 2002, The Cochrane database of systematic reviews.

Cardiac structure and function after revascularization versus medical therapy for renal artery stenosis: the ASTRAL heart echocardiographic sub-study

Rajan K. Patel, P. Mark, N. Ives, 2019, BMC Nephrology.

Revascularization versus medical therapy for renal-artery stenosis.

C. Baigent, N. Ives, P. Kalra, 2009, The New England journal of medicine.

Diffuse intrinsic pontine glioma treated with prolonged temozolomide and radiotherapy – Results of a United Kingdom phase II trial (CNS 2007 04)☆

P. Kearns, D. Hargrave, S. Bailey, 2013, European journal of cancer.

The utility of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with low-grade central nervous system (CNS) tumours: a systematic review

P. Kearns, A. Peet, S. Bailey, 2018, Journal of Neuro-Oncology.

First‐line double high‐dose chemotherapy and autologous stem cell transplantation versus single high‐dose chemotherapy and autologous stem cell transplantation in multiple myeloma

B. Djulbegovic, J. Bohlius, K. Wheatley, 2008 .

High-dose chemotherapy and autologous stem cell transplantation for multiple myeloma

B. Djulbegovic, J. Bohlius, K. Wheatley, 2003 .

Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)

J. Radford, S. Barrington, A. Davies, 2020, British journal of haematology.

Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia

C. Craddock, K. Wheatley, J. Loke, 2014, Annals of Hematology.

Adjuvant interferon therapy for melanoma.

M. Gore, N. Ives, K. Wheatley, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04)

D. Ellison, T. Jaspan, R. Grundy, 2022, Neuro-oncology advances.

Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.

R. Gray, K. Wheatley, R. Stevens, 1998, British journal of haematology.

Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia.

K. Wheatley, R. Stevens, G. Harrison, 2001, Blood.

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

C. Craddock, R. Hills, N. Russell, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

R. Hills, N. Russell, L. Kjeldsen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials

R. Hills, C. Harrison, K. Wheatley, 2005, Leukemia.

Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone

R. Gray, R. Zittoun, A. Burnett, 1999, Cancer.

Comparing results from long and short form versions of the Parkinson's disease questionnaire in a longitudinal study.

Richard Gray, Crispin Jenkinson, Keith Wheatley, 2015, Parkinsonism & related disorders.

University of Cost-effectiveness of dopamine agonists and monoamine oxidase B inhibitors in early Parkinson's disease

E. McIntosh, C. Clarke, N. Ives, 2021 .

RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.

R. Hills, S. Langabeer, D. Linch, 2005, Blood.

Bisphosphonates in multiple myeloma.

B. Djulbegovic, A. Glasmacher, J. Redzepovic, 2010, The Cochrane database of systematic reviews.

Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial.

A. Burnett, K. Wheatley, J. Craig, 2006, Blood.

Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.

R. Hills, M. McMullin, A. Goldstone, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AML in Children: The Medical Research Council Data

R. Gray, K. Wheatley, R. Stevens, 2001 .

Problems with up-front randomization in clinical trials.

R. Hills, A. Burnett, K. Wheatley, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

R. Hills, M. McMullin, A. Goldstone, 2007, Cancer.

REFINEMENT OF CYTOGENETIC CLASSIFICATION IN AML: DETERMINATION OF PROGNOSTIC SIGNIFICANCE OF RARE RECURRING CHROMOSOMAL ABNORMALITIES AMONGST 5635 YOUNGER ADULTS TREATED IN THE UK MRC TRIALS

R. Hills, D. Grimwade, C. Harrison, 2009 .

Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.

G. Vassal, C. Bollard, P. Adamson, 2020, The New England journal of medicine.

Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials

E. Kimby, F. Bosch, E. Montserrat, 1999 .

Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.

H. Heimpel, R. Peto, J. Hasford, 1997, Journal of the National Cancer Institute.

a copy of The impact of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with central system (CNS) tumours : Protocol for a systematic review and meta-analysis

P. Kearns, S. Bailey, K. Wheatley, 2019 .

Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial.

M. Watson, A. Goldstone, A. Burnett, 2004, European journal of cancer.

WARP - A multicentre prospective randomised controlled trial (RCT) of thrombosis prophylaxis with warfarin in cancer patients with central venous catheters (CVCs)

D. Kerr, D. Rea, L. Billingham, 2005 .

Results of treatment of children with refractory anaemia with excess blasts (RAEB) and RAEB in transformation (RAEBt) in Great Britain 1990–99

K. Wheatley, G. Harrison, I. Hann, 2002, British journal of haematology.

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

R. Hills, N. Russell, A. Hunter, 2013, Leukemia.

The Addition of Arsenic Trioxide to Low Dose Ara-C in Older Patients with AML Does Not Improve Outcome

R. Hills, N. Russell, A. Hunter, 2011, Leukemia.

Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.

A. Levin, P. Merkel, L. Girard, 2022, Health technology assessment.

Plasma exchange and glucocorticoid dosing in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis (PEXIVAS): protocol for a randomized controlled trial

P. Merkel, W. Clark, N. Ives, 2013, Trials.

Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting

B. Hero, S. Baruchel, K. Matthay, 2022, Cancer.

FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.

A. Mead, R. Hills, D. Linch, 2007, Blood.

The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

R. Hills, N. Russell, A. Burnett, 2012, British journal of haematology.

Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials

J. Kirkwood, A. Eggermont, N. Cascinelli, 2007 .

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

K Wheatley, D. Grimwade, C. Harrison, 1998, Blood.

myeloid leukemia following chemotherapy Genetic variation in XPD predicts treatment outcome and risk of acute

Alexandra G. Smith, G. Morgan, R. Hills, 2013 .

Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12.

E. van den Berg, R. Hills, D. Grimwade, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.

R. Hills, D. Linch, A. Goldstone, 2010, Blood.

Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.

R. Hills, A. Pizzey, K. Mills, 2005, Blood.

Molecular characterisation of patients with APL entered into the UK MRC ATRA trial: Relationship of PML breakpoint with additional cytogenetic abnormalities and outcome [Abstract]

S. Langabeer, D. Grimwade, P. Gorman, 1997 .

Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trial

A. Burnett, K. Wheatley, J. A. Liu Yin, 2001, British journal of haematology.

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All- Trans Retinoic Acid: Result of the Randomized MRC Trial

D. Grimwade, E. Solomon, A. Goldstone, 2022 .

Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival.

R. Hills, N. Russell, A. Hunter, 2013, Blood.

Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial

K. Wheatley, G. Harrison, I. Hann, 1999, Leukemia.

Retinoic Acid: Result of the Randomized MRC Trial All-Trans Predict Prognosis in Acute Promyelocytic Leukemia Treated With Presenting White Blood Cell Count and Kinetics of Molecular Remission

D. Grimwade, E. Solomon, A. Goldstone, 2013 .

D. Grimwade, E. Solomon, A. Goldstone, 2022 .

Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission.

R. Hills, N. Russell, A. Hunter, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial.

D. Grimwade, E. Solomon, A. Goldstone, 1999, Blood.

tandem duplications in patients with acute myeloid leukemia and have a significantly more favorable prognosis than FLT3 internal FLT3 tyrosine kinase domain mutations are biologically distinct from

A. Mead, R. Hills, D. Linch, 2013 .

The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial.

D. Grimwade, A. Goldstone, A. Burnett, 1999 .

Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial

G. Vassal, C. Bollard, P. Adamson, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of the randomized Intergroup trial Inter-B-NHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen.

James R. Anderson, C. Bollard, C. Patte, 2016 .

Low dose Ara-C versus low Dose Ara-C and Tipifarnib: result of the UK NCRI AML16 "Pick a Winner" comparison [Abstract]

R. Hills, N. Russell, A. Burnett, 2008 .

Does adjuvant vaccine therapy really have activity in malignant melanoma?

P. Lorigan, N. Ives, K. Wheatley, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lack of benefit of G-CSF on complete remission and possible increased relapse risk in AML: An MRC study of 800 patients [Abstract]

A. Burnett, A. Prentice, K. Wheatley, 1997 .

Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial.

R. Hills, N. Russell, L. Kjeldsen, 2009 .

A Sensitive Risk Score for Directing Treatment in Younger Patients with AML.

R. Hills, A. Goldstone, A. Burnett, 2006 .

What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML Trial

D. Grimwade, A. Burnett, K. Wheatley, 1997, Bone Marrow Transplantation.

Low Dose Ara-C Versus Hydroxyurea with or without Retinoid in Older Patients Not Considered Fit for Intensive Chemotherapy: The UK NCRI AML14 Trial.

M. McMullin, A. Goldstone, A. Burnett, 2004 .

Attempts to modulate chemoresistance in older patients with AML using PSC-833 - Results of the LRF AML14 trial

R. Hills, N. Russell, M. Pallis, 2003 .

Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features

P. Campbell, A. Green, A. Godfrey, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

J. Dongen, K. Wheatley, S. D. Graaf, 2010, Leukemia.

SAB – a promising new treatment to improve remission rates in AML in the elderly?

K. Wheatley, 2002, British journal of haematology.

Impact of Marrow Transplantation in Acute Myeloid Leukemia in First Complete Remission: Experience from MRC AML-10 Trial

A. Burnett, K. Wheatley, A. Goldstone, 1997 .

The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial

R. Hills, N. Russell, L. Kjeldsen, 2011 .

Does all-transretinoic acid (ATRA) have a role in non-APL acute myeloid leukaemia?: Results from 1666 patients in three MRC trials [Abstract]

R. Hills, A. Goldstone, A. Burnett, 2004 .

Fludarabine, cytosine arabinoside, granulocyte‐colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes

A. Burnett, K. Wheatley, D. Milligan, 2004, British journal of haematology.

randomized trial G-CSF and ATRA are not beneficial: results of the MRC AML-HR chemotherapy in high-risk acute myeloid leukemia, and addition of Fludarabine and cytosine are less effective than standard ADE

A. Burnett, K. Wheatley, J. Craig, 2013 .

Association between premature mortality and hypopituitarism

K. Wheatley, R. Hills, N. Holden, 2001, The Lancet.

The Impact of FLT3-ITD and NPM1 Mutational Status on the Outcome of ATRA Therapy in Patients with Non-APL AML: Results of the UK MRC AML12 Trial

R. Hills, D. Linch, M. Lazenby, 2008 .

Bisphosphonates in multiple myeloma.

H. Goldschmidt, B. Djulbegovic, A. Glasmacher, 2001, The Cochrane database of systematic reviews.

Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue

N. Sebire, M. Gaze, K. Wheatley, 2018, European Journal of Nuclear Medicine and Molecular Imaging.

The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison

R. Hills, N. Russell, A. Hunter, 2010 .

Stem Cell Transplants in Acute Myeloid Leukaemia (AML)

A. Burnett, K. Wheatley, L. Robinson, 1998 .

Allo and auto BMT reduce relapse risk in AML in CR1 but do not significantly improve overall survival Results of the MRC AML 10 trial

R. Gray, A. Burnett, K. Wheatley, 1996 .

A simple, robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom medical research council (MRC) AML10 trial.

R. Gray, A. Burnett, K. Wheatley, 1995 .

Evaluation of Prospective Detection of PML-RARA and RARA-PML Fusion Transcripts by Real-Time Quantitative PCR (RQ-PCR) To Direct Pre-Emptive Therapy with Arsenic Trioxide (ATO) in Acute Promyelocytic Leukemia (APL) Patients Treated in the UK MRC AML15 Trial.

R. Hills, D. Grimwade, E. Solomon, 2007 .

Effect of topical imiquimod as primary treatment for lentigo maligna: the LIMIT‐1 study

L. Billingham, K. Wheatley, N. Steven, 2017, The British journal of dermatology.

Frequency of CBF beta/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials. The MRC Adult Leukaemia Working Party.

S. Langabeer, D. Linch, A. Burnett, 1997, British journal of haematology.

Dose intensification in acute myloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's ATML9 study

R. Gray, K. Wheatley, J. Rees, 1996, British journal of haematology.

Prognostic importance of Sudan Black positivity: a study of bone marrow slides from 1386 patients with de novo acute myeloid leukaemia

R. Gray, P. Sherrington, D. Swirsky, 1991, British journal of haematology.

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature

P. Vyas, C. Craddock, S. Siddique, 2017, Clinical Cancer Research.

cytometry. IV. CD34 overexpression in acute myelogenous leukemia Leukemia-associated changes identified by quantitative flow

G. Janossy, A. Goldstone, D. Swirsky, 2011 .

Reply to S. Nagai et al

F. Lo‐Coco, R. Hills, D. Grimwade, 2010 .

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

R. Hills, N. Russell, A. Hunter, 2007 .

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

J. D. van der Walt, P. Campbell, A. Green, 2005, The New England journal of medicine.

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial

Keith Wheatley, R. Gray, A. Goldstone, 1998, The Lancet.

The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial

A. Goldstone, A. Burnett, K. Wheatley, 2002, British journal of haematology.

How to avoid bias when comparing bone marrow transplantation with chemotherapy.

R. Gray, K. Wheatley, R. Gray, 1991, Bone marrow transplantation.

Patterns of care and survival for adolescents and young adults with acute leukaemia – a population-based study

C. Stiller, K. Wheatley, S. Proctor, 1999, British Journal of Cancer.

VITATOPS, the VITAmins TO Prevent Stroke Trial: Rationale and Design of a Randomised Trial of B-Vitamin Therapy in Patients with Recent Transient Ischaemic Attack or Stroke (NCT00097669) (ISRCTN74743444)

C. Sudlow, D. Xavier, G. Hankey, 2007, International journal of stroke : official journal of the International Stroke Society.

Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia

P. Vyas, C. Craddock, S. Siddique, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cabergoline versus levodopa monotherapy

C. Clarke, N. Ives, R. Gray, 2004, Movement disorders : official journal of the Movement Disorder Society.

Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors

R. Doll, R. Peto, K. Wheatley, 1994, BMJ.

Guidelines on the management of acute myeloid leukaemia in adults

C. Craddock, D. Grimwade, G. Jackson, 2006, British journal of haematology.

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

R. Hills, D. Grimwade, C. Harrison, 2010, Blood.

PEPtalk2: results of a pilot randomised controlled trial to compare VZIG and aciclovir as postexposure prophylaxis (PEP) against chickenpox in children with cancer

M. Jit, J. Chisholm, J. Bate, 2018, Archives of Disease in Childhood.

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

D. Grimwade, C. Harrison, A. Goldstone, 2001, Blood.

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

R. Hills, D. Linch, A. Burnett, 2005, Blood.

PEPtalk: postexposure prophylaxis against varicella in children with cancer

P. Kearns, J. Chisholm, J. Bate, 2011, Archives of Disease in Childhood.

Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.

U. Dirksen, A. Craft, G. Le Teuff, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hyperfractionated Accelerated Radiotherapy (HART) with maintenance chemotherapy for metastatic (M1-3) Medulloblastoma--a safety/feasibility study.

D. Mitra, F. Saran, K. Wheatley, 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol

N. Fenwick, H. Gelderblom, J. Martín-Broto, 2019, Trials.

High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008.

J. Blay, U. Dirksen, A. Craft, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study

P. Campbell, A. Green, J. Marsden, 2005, The Lancet.

Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party

H. Kempski, K. Wheatley, G. Harrison, 2002, Leukemia.

Bisphosphonates in multiple myeloma.

B. Djulbegovic, A. Glasmacher, J. Redzepovic, 2010, The Cochrane database of systematic reviews.

A phase IIa trial of molecular radiotherapy with 177-lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma

M. Gaze, S. Wan, J. Bomanji, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21).

G. Janossy, A. Goldstone, D. Swirsky, 1996, Blood.

Treatment for myeloid leukaemia of Down syndrome: population‐based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials

R. Hills, C. Stiller, A. O'marcaigh, 2006, British journal of haematology.

A simple, robust, validated and highly predictive index for the determination of risk‐directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

R. Gray, A. Goldstone, A. Burnett, 1999, British journal of haematology.

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial

R. Gray, P. Sherrington, K. Wheatley, 1989, British journal of haematology.

Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).

U. Dirksen, N. Fenwick, S. Strauss, 2020, Journal of Clinical Oncology.

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.

Mike Clarke, K Wheatley, A Riccardi, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukemia.

G. Janossy, K. Wheatley, K. Ivory, 1995, Leukemia.

Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation.

K. Wheatley, Jayne S. Wilson, J. Marsden, 2016, Cancer treatment reviews.

Reply to response to Wheatley et al., "Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation" Cancer Treatment Reviews April 2016;45:76.

K. Wheatley, Jayne S. Wilson, J. Marsden, 2017, Cancer treatment reviews.

Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy.

Alexandra G. Smith, G. Morgan, R. Hills, 2004, Blood.

Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial

K. Wheatley, S. D. de Graaf, B. Gibson, 2011, British journal of haematology.

Relationship between FLT 3 mutation status , biologic characteristics , and response to targeted therapy in acute promyelocytic leukemia

R. Hills, A. Pizzey, K. Mills, 2005 .

Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials

R. Hills, D. Grimwade, C. Harrison, 2010 .

Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? – A statistician's view

K. Wheatley, 2002, British journal of haematology.

Cytogenetics of childhood AML from UK medical research council treatment trials, AML10 & 12.

R. Hills, D. Grimwade, C. Harrison, 2003 .

Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial

K. McHugh, J. Merks, G. Calareso, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human gastric perfusion: Evidence for non‐uniformity of blood flow

K. Wheatley, I. Chesner, M. Goldman, 1988, The British journal of surgery.

Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council.

R. Gray, R. Gray, A. Goldstone, 1997, Blood.

Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease

C. Clarke, N. Ives, R. Stowe, 2011, Movement disorders : official journal of the Movement Disorder Society.

Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.

C. Clarke, N. Ives, R. Stowe, 2010, The Cochrane database of systematic reviews.

Dopamine agonist therapy in early Parkinson's disease.

J. Ferreira, C. Clarke, N. Ives, 2008, The Cochrane database of systematic reviews.

Evaluating drug treatments for Parkinson's disease: how good are the trials?

R. Hills, C. Clarke, R. Stowe, 2002, BMJ : British Medical Journal.

Del (9q) AML: clinical and cytological characteristics and prognostic implications

L. Side, C. Harrison, J. Boultwood, 2005, British journal of haematology.

High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008.

U. Dirksen, A. Craft, R. Goldsby, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

D. Adu, N. Ives, P. Cockwell, 2003, BMJ : British Medical Journal.

A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia

R. Peto, F. Mandelli, R. Gray, 1998, British journal of haematology.

Randomised trial of prophylactic daily aspirin in British male doctors

R. Doll, R. Peto, C. Hennekens, 1988, British medical journal.

Improved outcome of acute myeloid leukaemia in Down’s syndrome

K. Wheatley, G. Harrison, I. Hann, 1999, Archives of disease in childhood.

Bortezomib for the treatment of multiple myeloma.

I. Coyne, K. Wheatley, P. Hayden, 2016, The Cochrane database of systematic reviews.

Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials

Keith Wheatley, Anthony V Moorman, A. Moorman, 2009, British journal of haematology.

Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients.

P. Lorigan, N. Ives, R. Stowe, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EVI1 expression in acute myeloid leukaemia

B. Bain, S. Langabeer, D. Grimwade, 2001, British journal of haematology.

Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.

P. Vyas, C. Craddock, J. Ward, 2016, Blood advances.

Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): Results of EURO-EWING 99-R2 randomized trial (EE99R2Loc).

U. Dirksen, B. Morland, I. Judson, 2016 .

Comparison of two chemotherapy regimens in Ewing sarcoma (ES): Overall and subgroup results of the Euro Ewing 2012 randomized trial (EE2012).

H. Gelderblom, S. Strauss, J. Whelan, 2020 .

Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma.

K. S. Hall, U. Dirksen, N. Fenwick, 2019, Journal of Clinical Oncology.

Need for a quantitative meta-analysis of trials of adjuvant interferon in melanoma.

M. Gore, N. Ives, K. Wheatley, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive importance of ulceration on the efficacy of adjuvant interferon-a (IFN): An individual patient data (IPD) meta-analysis of 15 randomized trials in more than 7,500 melanoma patients (pts).

J. Kirkwood, A. Eggermont, C. Garbe, 2014 .

UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma.

J. Larkin, P. Nathan, P. Lorigan, 2016 .

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

R. Hills, N. Russell, M. Dennis, 2009, British journal of haematology.

THE RETINOBLASTOMA GENE (RB1) IN ACUTE MYELOID LEUKAEMIA: ANALYSIS OF GENE REARRANGEMENTS, PROTEIN EXPRESSION AND COMPARISON OF DISEASE OUTCOME

R. Jamal, D. Linch, N. Thomas, 1996, British journal of haematology.

Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial

Keith Wheatley, Crispin Jenkinson, Niall Quinn, 2010, The Lancet Neurology.

Adjuvant interferon for melanoma.

N. Ives, K. Wheatley, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

The utility of routine surveillance screening with magnetic resonance imaging to detect tumor recurrence/progression in children with high‐grade central nervous system tumors: a systematic review

B. Phillips, P. Kearns, A. Peet, 2018, Pediatric blood & cancer.

University of Birmingham The utility of routine surveillance screening with magnetic resonance imaging to detect tumour recurrence/progression in children with high-grade central nervous system tumours

B. Phillips, P. Kearns, A. Peet, 2018 .

Comparison of anticipated and actual control group outcomes in randomised trials in paediatric oncology provides evidence that historically controlled studies are biased in favour of the novel treatment

P. Kearns, K. Wheatley, Jayne S. Wilson, 2011, Trials.

UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria

Marion F Walker, Rebecca Kandiyali, Catherine Sackley, 2016 .

Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1,613 patients entered into the UK MRC AML 10 trial.

R. Gray, D. Grimwade, C. Harrison, 1996 .

The impact of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumour recurrence in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis

P. Kearns, S. Bailey, C. Main, 2016, Systematic Reviews.

Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group.

K. Wheatley, P. Stewart, R. Hills, 2001, Lancet.

Randomized placebo‐controlled trial of granulocyte colony stimulating factor (G‐CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party

A. Goldstone, A. Burnett, K. Wheatley, 2009, British journal of haematology.

The Medical Research Council PT1 Trial in Essential Thrombocythemia.

P. Campbell, A. Green, J. Reilly, 2004 .

FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research—a systematic review and meta-analysis

K. Wheatley, J. Loke, J. Wilson, 2020, Systematic Reviews.

Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations

J. Bohlius, K. Wheatley, A. Engert, 2011, Leukemia & lymphoma.

Meta-analyses of randomised controlled trials (RCT) of warfarin and low molecular weight heparin (LMWH) for the prevention of venous thromboembolism (VTE) and death in cancer patients

R. Hills, K. Wheatley, A. Young, 2005 .

The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial.

R. Hills, N. Russell, A. Hunter, 2006 .

Commentary: Mendelian randomization--an update on its use to evaluate allogeneic stem cell transplantation in leukaemia.

Richard Gray, Keith Wheatley, R. Gray, 2004, International journal of epidemiology.

Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial

Daniel W Rea, Andrew Stanley, Lucinda J Billingham, 2009, The Lancet.

Maintenance therapies for multiple myeloma

B. Djulbegovic, K. Wheatley, B. Miladinovic, 2016 .

Bevacizumab for children with relapsed & refractory high-risk neuroblastoma (RR-HRNB): Results of the BEACON-neuroblastoma randomized phase II trial - A European ITCC-SIOPEN trial

B. Morland, K. Wheatley, R. Ladenstein, 2019, Annals of Oncology.

Temozolomide versus irinotecan-temozolomide for children with relapsed and refractory high risk neuroblastoma (RR-HRNB): Results of the BEACON-Neuroblastoma randomized phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC) - International Society of Pediatric Oncology Europe N

P. Kearns, E. Thébaud, K. Wheatley, 2019, Journal of Clinical Oncology.

Early versus deferred treatment for early stage multiple myeloma.

B. Djulbegovic, A. Glasmacher, K. Wheatley, 2003, The Cochrane database of systematic reviews.

Long term tapering versus standard prednisolone treatment for first episode of childhood nephrotic syndrome: phase III randomised controlled trial and economic evaluation

J. Deeks, E. Frew, N. Ives, 2019, BMJ.

Calcineurin Inhibitor Sparing With Mycophenolate in Kidney Transplantation: A Systematic Review and Meta-Analysis

D. Adu, P. Cockwell, R. Borrows, 2009, Transplantation.

Large-scale randomized evidence: trials and overviews.

K Wheatley, R. Collins, R. Peto, 2008 .

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.

A. Gray, C. Clarke, N. Ives, 2014, Lancet.

A modular questionnaire for the assessment of longterm quality of life in leukaemia patients: The MRC/EORTC QLQ-LEU

R. Zittoun, K. Wheatley, G. Solbu, 1996, Quality of Life Research.

Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization.

D. Clayton, K. Wheatley, 2003, Controlled clinical trials.

Aspirin use and chronic diseases

R. Collins, P. Sandercock, R. Doll, 1990 .

Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data

M. Taal, J. Emberson, C. Baigent, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease: a large pragmatic randomised controlled trial (PD REHAB).

M. Walker, C. Sackley, C. Clarke, 2016, Health technology assessment.

Lee Silverman Voice Treatment versus standard speech and language therapy versus control in Parkinson’s disease: a pilot randomised controlled trial (PD COMM pilot)

M. Brady, C. Sackley, S. Jowett, 2018, Pilot and Feasibility Studies.

Voice Treatment versus standard speech and language therapy versus control in Parkinson ’ s disease :

M. Brady, C. Sackley, S. Jowett, 2018 .

Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson’s disease (PD COMM pilot): study protocol for a randomized controlled trial

M. Brady, C. Sackley, S. Jowett, 2014, Trials.

An occupational therapy intervention for residents with stroke related disabilities in UK care homes (OTCH): cluster randomised controlled trial

M. Walker, C. Watkins, B. Sheehan, 2015, BMJ : British Medical Journal.

Understanding meta-analysis

Keith Wheatley, K. Wheatley, 2001 .

Home-based Reach-to-Grasp training for people after stroke is feasible: a pilot randomised controlled trial

A. Turton, F. van Wijck, P. van Vliet, 2017, Clinical rehabilitation.

Alcohol and coronary heart disease reduction among British doctors: confounding or causality?

R. Doll, R. Peto, K. Wheatley, 1997, European heart journal.

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease: A Randomized Double-Blind Trial

M. Landray, J. McMurray, M. Taal, 2018, Circulation.

Intensity-modulated arc therapy to improve radiation dose delivery in the treatment of abdominal neuroblastoma.

M. Gaze, H. Mandeville, D. D’Souza, 2013, Future oncology.

Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials

D C Linch, K Wheatley, S. Langabeer, 1997, British journal of haematology.

Frequency of CBFβ/MYH11 fusion transcripts in patients entered into the U.K. MRC AML trials

S. Langabeer, D. Linch, A. Goldstone, 1997 .

Continuing uncertainty about the value of percutaneous revascularization in atherosclerotic renovascular disease: a meta-analysis of randomized trials.

P. Krijnen, N. Ives, P. Plouin, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma.

M. Gaze, K. Wheatley, Jayne S. Wilson, 2014, European journal of cancer.

Physiotherapy for Parkinson's disease: a comparison of techniques.

Rebecca Stowe, Keith Wheatley, Carl E Clarke, 2014, The Cochrane database of systematic reviews.

A cluster randomised controlled trial of an occupational therapy intervention for residents with stroke living in UK care homes (OTCH): study protocol

M. Walker, C. Watkins, M. Feltham, 2012, BMC Neurology.

Topical treatment of actinic keratoses in organ transplant recipients: a feasibility study for SPOT (Squamous cell carcinoma Prevention in Organ transplant recipients using Topical treatments)

T. Whitmarsh, J. Lear, C. Proby, 2022, The British journal of dermatology.

Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial.

U. Dirksen, A. Craft, G. Le Teuff, 2015, European journal of cancer.

Surgery for Parkinson’s disease: lack of reliable clinical trial evidence

R. Hills, C. Clarke, N. Ives, 2003, Journal of neurology, neurosurgery, and psychiatry.

Systematic review and meta-analysis of hydrocarbon exposure and the risk of Parkinson's disease.

C. Clarke, K. Morrison, Gladys Thomas, 2015, Parkinsonism & related disorders.

Physiotherapy intervention in Parkinson’s disease: systematic review and meta-analysis

Catherine Sackley, Rebecca Stowe, Keith Wheatley, 2012, BMJ : British Medical Journal.

Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial.

C. Bollard, C. Patte, S. Alexander, 2023, The Lancet. Haematology.

Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) therapy against myeloid and lymphoid cancers

F. Khanim, C. Bunce, M. Drayson, 2019, Contemporary clinical trials communications.

Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy

C. Clarke, N. Ives, C. Jenkinson, 2021, JAMA neurology.

Longer-term efficiency and safety of increasing the frequency of whole blood donation (INTERVAL): extension study of a randomised trial of 20 757 blood donors

J. Gallacher, J. Danesh, T. Peakman, 2019, The Lancet. Haematology.

The relationship between FLT3 mutation status: biological characteristics and outcome in patients with acute promyelocytic leukaemia.

R. Hills, K. Mills, D. Grimwade, 2003 .

Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients

Richard Gray, Keith Wheatley, Carl E Clarke, 2004, BMJ : British Medical Journal.

Physiotherapy and Occupational Therapy vs No Therapy in Mild to Moderate Parkinson Disease: A Randomized Clinical Trial.

M. Walker, C. Sackley, C. Clarke, 2016, JAMA neurology.

Should treatment for Parkinson's disease start immediately on diagnosis or delayed until functional disability develops?

C. Clarke, N. Ives, Smitaa Patel, 2011, Movement disorders : official journal of the Movement Disorder Society.

Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial

N. Fenwick, H. Gelderblom, J. Martín-Broto, 2022, The Lancet.

RESULTS OF a PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY)

J. Radford, V. Warbey, P. McKay, 2017 .

An Occupational Therapy intervention for residents with stroke-related disabilities in UK Care Homes (OTCH): cluster randomised controlled trial with economic evaluation.

M. Walker, C. Watkins, B. Sheehan, 2016, Health technology assessment.

Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) compared to conventional chemotherapy combined with lung irradiation in ewing sarcoma (ES) with primary lung metastases: Results of EURO-EWING 99-R2pulm randomized trial (EE99R2pul).

U. Dirksen, I. Judson, D. Hawkins, 2016 .

Long-term results of the MRC AML10 trial.

R. Hills, A. Goldstone, A. Burnett, 2006, Clinical advances in hematology & oncology : H&O.

University of Birmingham Interleukin-2 receptor monoclonal antibodies in renal transplantation

N. Ives, P. Cockwell, K. Wheatley, 2003 .

Risk-Stratified Sequential Treatment with Ibrutinib and Rituximab (IR) and IR-CHOP for De-Novo Post-Transplant Lymphoproliferative Disorder: Results of the Tidal Trial

A. Davies, P. McKay, K. Wheatley, 2021, Blood.

Cost‐utility analysis of deep brain stimulation surgery plus best medical therapy versus best medical therapy in patients with Parkinson's: Economic evaluation alongside the PD SURG trial

A. Gray, S. Gill, N. Ives, 2016, Movement disorders : official journal of the Movement Disorder Society.

The role of high-dose myeloablative chemotherapy with haematopoietic stem cell transplantation (HSCT) in children with central nervous system (CNS) tumours: protocol for a systematic review and meta-analysis

B. Phillips, P. Kearns, C. Main, 2015, Systematic Reviews.

University The role of high-dose myeloablative chemotherapy with haematopoietic stem cell transplantation (HSCT) in children with central nervous system (CNS) tumours

B. Phillips, P. Kearns, K. Wheatley, 2015 .

Randomized phase 2 trial of the combination of vincristine and irinotecan with or without temozolomide, in children and adults with refractory or relapsed rhabdomyosarcoma (RMS).

K. McHugh, G. Calareso, J. Chisholm, 2019, Journal of Clinical Oncology.

Outcome of acute myeloid leukaemias affecting core binding factor subunits: the UK MRC experience

S. Langabeer, D. Linch, A. Burnett, 1997 .

University of Birmingham Systematic review and meta-analysis of hydrocarbon exposure and the risk of Parkinson's disease

C. Clarke, K. Morrison, Gladys Thomas, 2014 .

Relationships between age at diagnosis, clinical features and outcome of therapy in children treated in the Medical Research Council trials for acute myeloid leukemia AML 10 and 12.

K. Wheatley, R. Stevens, G. Harrison, 2000 .

DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

Noah E. Berlow, Elaine C. Huang, T. Lagerweij, 2012 .

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

P. Vyas, N. Potter, A. Baruchel, 2019, Blood.

The paediatric hepatic international tumour trial (PHITT): clinical trial design in rare disease

P. Kearns, B. Morland, G. Tiao, 2015, Trials.

Correlation of response with progression-free (PFS) and overall (OS) survival in relapsed/refractory Ewing sarcoma (RR-ES): Results from the rEECur trial.

K. S. Hall, U. Dirksen, N. Fenwick, 2020 .

Inappropriate reporting and interpretation of subgroups in the AML-BFM 93 study

K. Wheatley, R. Hills, 2001, Leukemia.

R. Hills, D. Grimwade, C. Harrison, 2010, Blood.

Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.

P. Vyas, C. Craddock, J. Ward, 2016, Blood advances.

Survey of the use of platelet transfusions in centres participating in MRC leukaemia trials

Murphy, K. Wheatley, Wheatley, 1998, British journal of haematology.

Physiotherapy for Parkinson's disease: a comparison of techniques.

C. Sackley, C. Clarke, N. Ives, 2014, The Cochrane database of systematic reviews.

JAK2 V617F Mutation Identifies a Biologically Distinct Subtype of Essential Thrombocythemia Which Resembles Polycythemia Vera.

P. Campbell, A. Green, J. Marsden, 2005 .

Alcohol and coronary heart disease reduction among British doctors: confounding or causality?

R. Doll, R. Peto, K. Wheatley, 1997, European heart journal.

Results of Inter-B-NHL Ritux 2010 - Phase II Study of DA-EPOCH-R for Children and Adolescents with Primary Mediastinal Large B-Cell Lymphoma (PMLBL) on Behalf of European Intergroup for Childhood Non Hodgkin's Lymphoma (EICNHL) and Children's Oncology Group (COG)

C. Bollard, C. Patte, A. Uyttebroeck, 2017 .

High-dose chemotherapy and stem cell transplantation does not improve relapse-free or overall survival in women with high-risk breast cancer.

R. Carlson, K. Wheatley, 2004, Cancer treatment reviews.

Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients

C. Counsell, C. Clarke, N. Ives, 2004, BMJ : British Medical Journal.

Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials

D. Adu, N. Ives, P. Cockwell, 2003, BMJ : British Medical Journal.

Angioplasty and STent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far

N. Ives, P. Kalra, G. Lipkin, 2007, Journal of Human Hypertension.

Calcineurin Inhibitor Sparing With Mycophenolate in Kidney Transplantation: A Systematic Review and Meta-Analysis

D. Adu, P. Cockwell, R. Borrows, 2009, Transplantation.

A cluster randomised controlled trial of an occupational therapy intervention for residents with stroke living in UK care-homes

C. Watkins, C. Sackley, J. Mant, 2013 .

A cluster randomised controlled trial of an occupational therapy intervention for residents with stroke living in UK care-homes

C. Watkins, C. Sackley, J. Mant, 2013 .

Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations

J. Bohlius, K. Wheatley, A. Engert, 2011, Leukemia & lymphoma.

The effectiveness and safety of proton beam radiation therapy in children with malignant central nervous system (CNS) tumours: protocol for a systematic review

P. Kearns, C. Main, K. Wheatley, 2016, Systematic Reviews.

Treatment Reasons, Resource use and Costs of Hospitalisations in People with Parkinson's: Results from a Large Rct.

A. Gray, C. Clarke, N. Ives, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Clinical Significance of MPL Mutations in Essential Thrombocythemia: Analysis of the PT-1 Cohort.

P. Campbell, A. Green, W. Erber, 2007 .